Clinical Trial Update: Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors

View source ↗

Summary

A post-authorisation safety study comparing empagliflozin with DPP-4 inhibitors in adults with type 2 diabetes reports results on risks including liver injury, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• DPP-4 inhibitors
• Empagliflozin (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Status: COMPLETED | Results posted: 2024-11-15